1. Introduction {#s0005}
===============

In normal cells, KRas is activated by upstream tyrosine kinases, including EGFR, for further downstream signaling through the RAF-MEK-ERK cascade. However, in several human cancers, mutated KRas is constitutively active and does not require upstream activation, thus fulfilling one of the hallmarks of cancer cells ([@bb0070]). *Kras*^*G12D*^ is the driving oncogenic mutation of pancreatic ductal adenocarcinoma (PDAC), one if not the most fatal human cancers ([@bb0010]). PDAC develops through preneoplastic lesions originating from acinar-to-ductal metaplasia (ADM) ([@bb0005], [@bb0130]). Despite being constitutively active, KRas^G12D^ requires upregulated expression of the tyrosine kinase EGF receptor (EGFR) for ADM development ([@bb0020], [@bb0150]) and its downstream target *Rac1* for correct actin organization ([@bb0075], [@bb0130]). However, how oncogenic KRas and EGFR cooperate for ADM development remains still unclear.

EGFR requires ligand binding for activation, activated EGFR signals from the plasma membrane to downstream targets and is subsequently internalized through endocytosis ([@bb0055], [@bb0155], [@bb0195]). Endocytosis controls cellular homeostasis, is tightly regulated and involves several mechanisms that can be both receptor-driven and receptor-independent. Fluid-phase endocytosis (FPE) includes endocytic pathways that have fluid phase markers as cargos ([@bb0040], [@bb0065], [@bb0185]). Recent work supports a regulatory role of endocytosis in the net signaling output of malignant cells ([@bb0105], [@bb0140], [@bb0145], [@bb0165], [@bb0175]). However, the impact of an endocytic mechanism, in particular of FPE, in the early development of preneoplastic transformation in the pancreas has not been defined yet.

Here, we show that sustained FPE is required for the development of ADM. Our data indicate that oncogenic KRas^G12D^ in acinar cells leads to an EGFR-dependent increase in FPE to drive the formation of precancerous lesions and that an increase in FPE can lead to ADM independently of EGFR expression. We also provide *in vivo* evidence that the KRas-induced increase in FPE is dependent on N-WASP expression. Thus, our data provide a new link between oncogenic KRas and sustained FPE during pancreatic cancer initiation.

2. Materials and Methods {#s0010}
========================

*Ptf1a*^*Cre/wt*^, *Kras*^*LSL-G12D/wt*^, *Egfr*^*Δ/Δ*^, ^*Δ/Δ*^, *N-Wasp*^*Δ/Δ*^ and *p53*^*Δ/Δ*^ strains have previously been described ([@bb0020], [@bb0075], [@bb0080], [@bb0120]). Experiments were conducted in accordance with the German Federal Animal Protection Laws and were approved by the Institutional Animal Care and Use Committees of the Technical University of Munich.

2.2. Human Samples {#s0020}
==================

This study conformed to the Declaration of Helsinki and was approved by the ethics committee of the Technical University of Munich. Informed consent was obtained from all patients included in the study (project number 365/13). Human acinar epithelial explants were isolated from the normal tissue surrounding surgically resected human PDAC.

2.3. Acinar Epithelial Explants {#s0025}
===============================

Pancreatic epithelial explants were prepared as described in ([@bb0125]). Recombinant mouse EGF (R&D Systems; final concentration, 25 ng/ml) was added when indicated. Compounds were added once to the media the same day of isolation (defined as day 1). Wortmannin, cytochalasin D (Sigma), monensin (Calbiochem) and refametinib (Selleckchem) were used. For ADM quantification, acinar explants were seeded at least in triplicates and ADM was quantified from 3 to 8 optical fields per well by counting rounded acinar-cell clusters and flat duct-like cell clusters lining a hole. Quantification of ADM was confirmed by immunofluorescence or western blot analysis for CK19 expression in the ductal structures.

2.4. Fluid-phase Endocytosis (FPE) Assays {#s0030}
=========================================

Two methods described in the supplementary information (SI) were used as a functional assay for the quantification of receptor-independent endocytosis. All FPE assays were performed one day after isolation of acinar explants if not other specified.

2.5. Immunoisolation {#s0035}
====================

RAB5 + endosomes were isolated using MACS technology. See the SI section.

2.6. Immunohistochemistry and Immunofluorescence {#s0040}
================================================

Standard staining techniques were used. See the SI section.

2.7. Western Blots {#s0045}
==================

Standard western blotting was used. For a list of antibodies used see the SI section.

2.8. Statistics {#s0050}
===============

Statistical analyses were performed using unpaired, two-tailed student\'s *t*-test or Mann--Whitney test. In all box plots the central line is the median of the data and the whiskers represent maximum and minimum values.

3. Results {#s0055}
==========

3.1. FPE Is Increased in Oncogenic KRas-mediated Preneoplastic Development {#s0060}
--------------------------------------------------------------------------

PDAC patients have mutated KRas in about 95% of the cases ([@bb0085]). Using cBioBiortal ([@bb0030], [@bb0060]) we found that up to 10% of genes involved in the endolysosomal system were upregulated in PDAC patients ([Fig. 1](#f0005){ref-type="fig"}A and [Supplementary Table 1](#ec0005){ref-type="supplementary-material"}). When the tumors were dichotomized for alterations in these genes, patients with respective alterations had a significantly reduced survival ([Fig. S1](#ec0005){ref-type="supplementary-material"}A).

Human and mouse PDAC can originate from pancreatic acinar cells through acinar-to-ductal metaplasia (ADM) ([@bb0005], [@bb0130]). Conditional *Ptf1a*^*Cre/wt*^;*Kras*^*LSL-G12D/*wt^ mice (*Kras*^*G12D*^) develop ADM within few weeks postnatally ([Fig. S1](#ec0005){ref-type="supplementary-material"}B). RAB5 is the rate-limiting component of the endocytic machinery, thus we next analyzed expression of RAB5. RAB5 was strongly expressed in ADM lesions in *Kras*^*G12D*^ mice ([Fig. 1](#f0005){ref-type="fig"}B), and both RAB5 and active RAB5-GTP increased in pancreatic whole tissue lysates of *Kras*^*G12D*^ mice with age ([Fig. S1](#ec0005){ref-type="supplementary-material"}E). To further analyze endocytic pathways during ADM, we used primary acinar epithelial explants from *Kras*^*G12D*^ mice (termed *Kras*^*G12D*^ explants), which developed ADM *in vitro* within 3 days and upregulated EGFR expression when cultivated in 3D-collagen matrix ([Fig. S1](#ec0005){ref-type="supplementary-material"}B-D). Similarly, wild type explants develop ADM when treated with EGF ([Fig. S1](#ec0005){ref-type="supplementary-material"}F) ([@bb0020]). Notably, both *Kras*^*G12D*^ and wild type explants can be inhibited by the allosteric MEK1/2 inhibitor refametinib as previously shown ([@bb0020], [@bb0090]) ([Fig. S1](#ec0005){ref-type="supplementary-material"}F). Thus, both *Kras*^*G12D*^ and EGF-treated wild type acinar explants mimic ADM and depend on activation of the EGFR-MEK-ERK pathway, providing a model to further investigate the molecular mechanisms underlying ADM.

As for murine explants, acinar explants from human pancreatic tissue developed ADM *in vitro* within few days ([Fig. 1](#f0005){ref-type="fig"}C,D) in agreement with previous studies ([@bb0045]). We next analyzed the uptake of fluid-phase markers, which increased as ADM progressed both in human ([Fig. 1](#f0005){ref-type="fig"}E) and in mouse explants ([Figs. 1](#f0005){ref-type="fig"}F, [S1](#ec0005){ref-type="supplementary-material"}G). Notably, this applied both for *Kras*^*G12D*^- and EGF- driven ADM. This result was supported by the observation that the number of vesicles positive for EEA1 increased from day 1 to day 3 during ADM in *Kras*^*G12D*^ explants ([Fig. S1](#ec0005){ref-type="supplementary-material"}H-I), while neither total EEA1 nor total RAB5 expression increased in *Kras*^*G12D*^ explants (not shown). Next, we investigated if oncogenic *KRas* could influence FPE levels in mouse acinar cells. FPE was significantly increased in freshly isolated *Kras*^*G12D*^ explants compared to controls ([Fig. 1](#f0005){ref-type="fig"}G). To confirm this result *in vivo*, we measured dextran uptake in 4 weeks old mice; at this age, acini from wild type and *Kras*^*G12D*^ mice were morphologically indistinguishable and both express the acinar marker amylase ([Fig. 1](#f0005){ref-type="fig"}H). FPE was significantly increased in the pancreata of *Kras*^*G12D*^ mice ([Fig. 1](#f0005){ref-type="fig"}I). A further type of endocytosis called macropinocytosis is upregulated in oncogenic *Kras*^*G12D*^ transformed cells ([@bb0035]), however FPE levels were unaffected in a panel of human pancreatic cell lines with or without oncogenic *KRas* mutation ([Fig. S1](#ec0005){ref-type="supplementary-material"}J). Thus, fluid-phase endocytosis is induced by oncogenic KRas in acinar cells before development of ADM *in vivo* and is not regulated by oncogenic *KRas* once cells are transformed.

3.2. FPE increases while ADM Occurs and is EGFR-dependent {#s0065}
---------------------------------------------------------

We next took advantage of the compounds monensin and wortmannin that affect the endolysosomal system among other effects. Monensin increases pH in intracellular organelles, inhibits receptor recycling and perturbs the endomembrane system. Wortmannin perturbs endocytosis by inhibition of phosphoinositide 3-kinase ([@bb0110], [@bb0180]). First, we used the two compounds to assess whether they can be used to inhibit FPE in acinar explants; both compounds reduced FPE ([Fig. 2](#f0010){ref-type="fig"}A). Second, we looked at the effect of the two compounds on ADM; both drugs inhibited ADM *in vitro* after 3 days of culture in a dose-dependent manner and were not toxic ([Figs. 2](#f0010){ref-type="fig"}B-C, [S2](#ec0005){ref-type="supplementary-material"}C). P-ERK was reduced upon pharmacological treatment and was still low at day 3 ([Figs. 2](#f0010){ref-type="fig"}D, [S2](#ec0005){ref-type="supplementary-material"}B). Similar results were obtained for EGF-treated wild type explants ([Fig. S2](#ec0005){ref-type="supplementary-material"}A, D--E) inhibitors affect FPE in acinar explants through perturbation of the Golgi apparatus, which is intimately connected to the endomembrane-system. Although the inhibitory effect of these compounds on ADM may be due to their actions on other pathways such as PI3K, these data suggest a potential involvement of FPE in acinar-to-ductal metaplasia that was further elucidated as described below.

Since reduction of P-ERK may be responsible for the blockade of ADM, we further analyzed the pancreatic cancer cell lines Capan1 and BxPc3. Here, monensin reduced FPE rates but increased P-ERK ([Fig. S2](#ec0005){ref-type="supplementary-material"}F--G). This result supports a direct drug effect on FPE, while down regulation of P-ERK may be secondary in acinar cells but not in fully transformed cancer cells.

We next investigated pathways potentially involved in the regulation of fluid-phase endocytosis during ADM. Activation of P-ERK occurs during both KRas and EGF-mediated ADM. Thus, we investigated whether P-ERK is required for the increase in FPE levels by using the MEK inhibitor refametinib that inhibited P-ERK activation in acinar explants ([Fig. 2](#f0010){ref-type="fig"}E). Refametinib did not affect FPE levels ([Fig. 2](#f0010){ref-type="fig"}F). We conclude that the increase of FPE does not require P-ERK activation in this context. Endocytosis is regulated by various mechanisms and some of them involve actin and the small GTPase RAC1 ([@bb0040]). Moreover, we have previously shown that RAC1-dependent actin polymerization is required for ADM in a mouse model with conditional deletion of *Rac1* (*Rac1*^*Δ/Δ*^) ([@bb0075]). Thus, we hypothesized a link between RAC1-regulated actin polymerization and the increase in fluid-phase endocytosis and used a pharmacological and genetic approach to test this hypothesis. We could block the increase of FPE upon EGF treatment in acinar explants both by pharmacological inhibition of actin polymerization with cytochalasin D (CytD) and by genetic depletion of *Rac1* using *Rac1*^*Δ/Δ*^ mice ([Fig. 2](#f0010){ref-type="fig"}G-H). In agreement with these results, FPE was reduced also by genetic depletion of *Rac1* in a *Kras*^*G12D*^ background using acinar explants from *Rac1*^*Δ/*Δ^;*Kras*^*G12D*^ mice ([Fig. 2](#f0010){ref-type="fig"}I). Hence, the increase of the fluid-phase endocytosis rates relies on RAC1-dependent actin polymerization during ADM.

In the canonical EGFR signaling pathway, activation of EGFR is required for KRas downstream signaling. Both constitutive active KRas^G12D^ and EGFR activation lead to ADM. However, genetic concomitant activation of oncogenic KRas and loss of EGFR in murine pancreas (*Kras*^*G12D*^;*Egfr*^*Δ/Δ*^) impairs ADM development ([@bb0020]). Since the amount of EEA1-positive vesicles increased in *Kras*^*G12D*^ but not *Kras*^*G12D*^;*Egfr*^*Δ/Δ*^ explants with time ([Fig. S1](#ec0005){ref-type="supplementary-material"}I), we next analyzed FPE using a functional dextran uptake assay performed on freshly isolated acinar explants. We found that explants lacking EGFR had reduced FPE rates ([Fig. 2](#f0010){ref-type="fig"}J--K). We conclude that oncogenic KRas requires EGFR for sustained fluid-phase endocytosis.

3.3. Variations in Plasma Membrane Tension Increase FPE and Induce ADM independently of EGFR {#s0070}
--------------------------------------------------------------------------------------------

We next aimed to address the role of EGFR-independent FPE. Variations in plasma membrane tension caused by changes in osmolarity modulate endocytosis ([@bb0015]). Since *Kras*^*G12D*^*;Egfr*^*Δ/Δ*^ mice do not develop tumors ([@bb0020]) and thus no PDAC cell lines could be established from this model, we used *Kras*^*G12D*^;*p53*^*Δ/Δ*^*;Egfr*^*Δ/Δ*^ mice to isolate and culture primary tumor cells with active oncogenic KRas lacking EGFR, and used these cells for stable expression of EGFR ([Fig. S3](#ec0005){ref-type="supplementary-material"}A). Treatment with hypoosmolar medium increased FPE in all cell lines, thus this method is suitable to induce FPE in a receptor-independent manner ([Fig. S3](#ec0005){ref-type="supplementary-material"}B--C). We next applied hypoosmolar medium to wild type explants. Here, FPE increased and induced ADM ([Fig. 3](#f0015){ref-type="fig"}A-B) in concomitance to activation of P-ERK and P-AKT ([Figs. 3](#f0015){ref-type="fig"}C, [S3](#ec0005){ref-type="supplementary-material"}D). CytD inhibited both FPE and ADM in this setting and was not toxic as evaluated by LDH-assay ([Fig. S3](#ec0005){ref-type="supplementary-material"}E--G). Thus, hypoosmotic stress-induced ADM is characterized by similar features as EGF-induced ADM.

Since *Kras*^*G12D*^;*Egfr*^*Δ/Δ*^ explants do not develop ADM *in vitro* under our standard conditions ([Fig. 3](#f0015){ref-type="fig"}D) ([@bb0020]), we next treated them with hypoosmolar medium, which increased endocytosis ([Fig. 3](#f0015){ref-type="fig"}E) and induced a partial rescue of the ADM phenotype ([Fig. 3](#f0015){ref-type="fig"}F--G) and P-ERK activation that persisted at day 3 ([Fig. 3](#f0015){ref-type="fig"}H). P-ERK activation was observed also in *Kras*^*G12D*^ explants after hypoosmotic treatment ([Fig. 3](#f0015){ref-type="fig"}H). Similarly, hypoosmolar medium partially induced ADM *in vitro* in *Egfr*^*Δ/Δ*^ explants ([Fig. S3](#ec0005){ref-type="supplementary-material"}H). In a second experimental approach, a mechanical strain was applied, since this may affect endocytosis ([@bb0015]). Mechanical strain slightly increased FPE and induced duct-like structures and P-ERK activation in *Kras*^*G12D*^*;Egfr*^*Δ/Δ*^ explants ([Fig. S4](#ec0005){ref-type="supplementary-material"}A--D). In summary, a receptor-independent increase of FPE is sufficient to overcome the requirement of EGFR for the development of duct-like structures and ERK phosphorylation in a three-dimensional explant model for acino-ductal metaplasia.

To gain further molecular insights, we analyzed ADM lesions by confocal imaging. We observed a partial overlap of ERK1 with RAB5 ([Fig. 3](#f0015){ref-type="fig"}I). We next immunoisolated the RAB5 + fraction from pancreatic tissue of wild type and *Kras*^*G12D*^ mice. EEA1 was detected in the RAB5 + fraction (magnetic fraction, MF), while the plasma membrane marker E-cadherin (CDH1) was absent, confirming successful isolation of the early endosomal fraction ([Fig. 3](#f0015){ref-type="fig"}J). Part of total ERK was found in the MF fraction of *Kras*^*G12D*^ pancreata only ([Fig. 3](#f0015){ref-type="fig"}K), in agreement with the confocal data. We next performed a mass spectrometry analysis of the RAB5 + fraction of *Kras*^*G12D*^ pancreatic tissue to identify proteins bound to early endosomes. Here, IQGAP1 was found in the top 8 hits present in the high molecular weight fraction ([Supplementary Table 2](#ec0005){ref-type="supplementary-material"}). RAB5 interacts with IQGAP1, which is a scaffold protein that modulates ERK activation ([@bb0095], [@bb0100]). Accordingly, IQGAP1 was found in the MF of *Kras*^*G12D*^ pancreatic tissue together with RAB5 ([Fig. S4](#ec0005){ref-type="supplementary-material"}E). Thus, one possible mechanism may be a scaffold function of early endosomes together with IQGAP1 for sustained ERK activation to drive ADM.

3.4. Sustained FPE Precedes ERK Activation Following Hypoosmotic Treatment {#s0075}
--------------------------------------------------------------------------

In order to investigate whether an increase in FPE is important for MEK/ERK activation, we looked for the effect of MEK inhibition on the hypoosmolar medium-induced ADM. *Kras*^*G12D*^ acinar explants were isolated and treated with hypoosmolar medium for five minutes to induce FPE ([Figs. S4](#ec0005){ref-type="supplementary-material"}F and [4](#f0020){ref-type="fig"}A). The MEK inhibitor refametinib was added immediately after the hypoosmotic treatment ([Fig. S4](#ec0005){ref-type="supplementary-material"}F). Refametinib did not reduce the amount of FPE ([Fig. 4](#f0020){ref-type="fig"}A), which is in line with the results obtained with the EGF-induced FPE ([Fig. 2](#f0010){ref-type="fig"}F). In contrast, refametinib inhibited hypoosmotic stress-induced ADM *in vitro* ([Figs. 4](#f0020){ref-type="fig"}B-C and [S4](#ec0005){ref-type="supplementary-material"}G). Thus, hypoosmotic stress-induced ADM is dependent of MEK/ERK activation like EGF- and *Kras*^*G12D*^-dependent ADM. These results also indicate that most likely an increase of FPE precedes MEK/ERK activation.

3.5. Oncogenic-Kras-driven Preneoplastic Development Relies on N-Wasp {#s0080}
---------------------------------------------------------------------

IQGAP1 interacts, among many other proteins, with N-WASP (the homolog of human *WASL*), an actin nucleation factor that regulates EGFR internalization and degradation ([@bb0190], [@bb0025]). In PDAC patients, *EGFR* and *WASL* mRNA expression correlated each other and with the expression of early endosomal genes *EEA1* and *RAB5A* but not with the late endosomal genes *RAB7* and *RAB9* ([Fig. 5](#f0025){ref-type="fig"}A). In *Kras*^*G12D*^ mice, we found expression of N-WASP in precursor lesions as well as in PDAC ([Figs. 5](#f0025){ref-type="fig"}B, [S5](#ec0005){ref-type="supplementary-material"}A), while N-WASP was absent in *Kras*^*G12D*^*;Egfr*^*Δ/Δ*^ pancreata ([Fig. 5](#f0025){ref-type="fig"}C). These data suggest a link between N-WASP, the endosomal compartment and tumor initiation. Thus, we generated mice with conditional pancreas-specific deletion of *N-Wasp* with and without concomitant activation of oncogenic *Kras*^*G12D*^.

*N-Wasp*^*Δ/Δ*^ and *Kras*^*G12D*^*;N-Wasp*^*Δ/Δ*^ mice were viable and born at Mendelian ratio. *N-Wasp*^*Δ/Δ*^ pancreata showed no abnormalities ([Fig. S5](#ec0005){ref-type="supplementary-material"}B) and FPE levels in *N-Wasp*^*Δ/Δ*^ explants were unaffected ([Fig. S5](#ec0005){ref-type="supplementary-material"}C). Three-months-old *Kras*^*G12D*^*;N-Wasp*^*Δ/Δ*^ mice, which did not express N-WASP ([Fig. 5](#f0025){ref-type="fig"}D), presented large areas with acinar tissue, fatty metaplasia and infiltrating cells ([Fig. S5](#ec0005){ref-type="supplementary-material"}D). Notably, *Kras*^*G12D*^*;N-Wasp*^*Δ/Δ*^ mice showed significantly less ADM lesions compared to *Kras*^*G12D*^ mice and developed no PanIN lesions ([Figs. 5](#f0025){ref-type="fig"}E-G, [S5](#ec0005){ref-type="supplementary-material"}E). Acinar cells did not express P-ERK in the pancreas of neither *Kras*^*G12D*^ nor *Kras*^*G12D*^*;N-Wasp*^*Δ/Δ*^ mice at the age of four 4 weeks ([Fig. S5](#ec0005){ref-type="supplementary-material"}I). At the age of three months, *Kras*^*G12D*^ mice showed diffuse P-ERK expression in ADM land PanIN lesions and acinar cells, while *Kras*^*G12D*^*; N-Wasp*^*Δ/Δ*^ mice did not express P-ERK in the morphologically appearing normal acinar cells ([Fig. 5](#f0025){ref-type="fig"}H).

In order to confirm the requirement of *N-Wasp* for ADM, we isolated acinar explants from 4 weeks old *Kras*^*G12D*^*;N-Wasp*^*Δ/Δ*^ mice which did not express N-WASP ([Supp. Fig. 5](#ec0005){ref-type="supplementary-material"}F). *Kras*^*G12D*^*;N-Wasp*^*Δ/Δ*^ explants did not develop ADM while maintaining an acinar phenotype ([Fig. 5](#f0025){ref-type="fig"}I-J). We next determined fluid-phase endocytosis rates in *Kras*^*G12D*^*;N-Wasp*^*Δ/Δ*^ explants that were significantly reduced ([Fig. 5](#f0025){ref-type="fig"}K), supporting the requirement of FPE for ADM *in vivo*. In agreement with these results, a cell line generated from a *Kras*^*G12D*^*;N-Wasp*^*Δ/Δ*^ mouse and lacking N-WASP expression had reduced FPE compared to control cells ([Fig. S5](#ec0005){ref-type="supplementary-material"}G--H). Thus, we provide *in vivo* genetic evidence that N-WASP is required for KRas-driven ADM development and sustained FPE.

4. Discussion {#s0085}
=============

Mutant KRas is involved in the development of many malignancies and is the sole oncogenic driver in PDAC ([@bb0050], [@bb0160]). *S*ignal transduction of the KRas pathway can take place both at the plasma membrane and in the endosomal compartment; however, the relevance of the latter in a physiological context is largely unknown ([@bb0055], [@bb0135]). Oncogenic KRas drives pancreatic acinar cells to develop PDAC through a process of ADM in cooperation with EGFR signaling ([@bb0020], [@bb0150]). KRas^G12D^ increases the levels of mitochondrial reactive oxygen species to increase *EGFR* transcription and also leads to increased macropinocytosis in transformed cells ([@bb0035], [@bb0115]). However; whether KRas requires the endocytic compartment for preneoplastic development is largely unknown.

Here, we used three-dimensional cultures of acinar epithelial explants to investigate the role of fluid-phase endocytosis in ADM development. The benefits of this method are: (i) explants expressing oncogenic KRas are not yet transformed; (ii) they develop ductal structures over time without proliferation; (iii) they are cultivated in three-dimensional collagen matrices, mimicking the *in vivo* cell morphological changes during ADM. We show that acinar exocrine tissue under physiological conditions has low fluid-phase endocytosis, which increases upon activation of KRas^G12D^ and requires expression of EGFR. An increase in FPE levels of acinar explants in response to changes in variations in plasma membrane tension is sufficient to induce ADM independently of EGFR expression and *vice versa* pharmacological inhibition of endocytosis impairs ADM *in vitro*. Several limitations need consideration: (i) we cannot exclude the involvement of FPE-independent pathways or mechanisms after the hypoosmotic treatment and/or by the mechanical strain applied; (ii) the pharmacological approaches are not specific for FPE, but also affect other pathways such as the PI3K and lysosomal pathways; (iii) the genetic deletion of *Rac1* and *N-Wasp* may involve also pathways other than FPE. Nevertheless, our data suggest that the requirement of EGFR for KRas^G12D^-induced ADM may be through regulation of FPE since also the PI3K pathway is connected to the endosomal function ([@bb0170]).

Fluid-phase endocytosis involves several endocytic mechanisms that are characterized by fluids as a cargo (reviewed in ([@bb0040])). While we did not characterize further the mechanism regulating FPE involved during ADM, we show here that the central regulatory role of RAC1 in ADM formation may be in part through actin-dependent regulation of fluid-phase endocytosis.

Mechanistically, we hypothesize that RAB5 + early endosomes may act as a scaffold for ERK activation. The increase in ERK phosphorylation goes along with the increase of FPE and conversely, inhibition of MEK/ERK activation does not affect the increase of FPE but inhibits ADM following perturbations in the plasma membrane supporting this hypothesis; additionally, IQGAP1, which has been shown to be required for ERK activation in KRas-driven tumors, interacts with early endosomes and is potentially involved in this pathway ([@bb0095], [@bb0100]). This working model is also supported by the observation that part of the intracellular ERK pool associates with the RAB5 + endosomal compartment in ADM lesions. Notably, IQGAP1 is known to interact with the actin-nucleation factor N-WASP ([@bb0190]), which is intimately connected to EGFR protein expression because it regulates its internalization ([@bb0025]) and expression of both *EGFR* and *WASL* positively correlates in human expression data as shown here. Here we show that N-WASP is upregulated during early pancreatic carcinogenesis. Conditional deletion of *N-Wasp* in the *KRas^G12D^* model impaired development of preneoplastic lesions by reducing FPE in acinar tissue, thus supporting the *in vivo* relevance of our findings and highlighting the causative role of N-WASP-dependent FPE for the development of precancerous lesions.

In summary, oncogenic KRas-induced increase in fluid-phase endocytosis has a key role during cellular transdifferentiation in pancreatic acinar cells. This result supports emerging evidence for endocytosis playing a crucial role in regulating the signaling output of the cells ([@bb0055], [@bb0145], [@bb0165], [@bb0175]). More insights into the crucial regulatory function of the endocytic compartment in PDAC development will help understand the complex role of KRas-dependent signaling with the potential for novel targeting approaches.
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![FPE is increased in oncogenic KRas-mediated preneoplastic development.\
(A) Genetic alterations in genes involved in the endolysosomal system in human PDAC samples (TGCA provisional, *N* = 145 patients).\
(B) Pancreata from mice of the indicated genotypes were analyzed by immunofluorescence. A rabbit *anti*-RAB5 antibody was used. Normal rabbit serum was used as matched negative control. Images were taken with the same exposition time for each slide. The bright green dots seen in each panel are erythrocytes. Asterisks highlight preneoplastic lesions expressing high RAB5 levels. Scale bars = 50 μM.\
(C) Top: schematic representation of acinar cell explants. Bottom: immunofluorescence staining of human acinar explants for the acinar cell marker amylase and the ductal marker cytokeratin 19 (CK19).\
(D) Quantification of ADM using human explants in collagen matrix. Each dot represents the number of structures/optical field. Red lines: mean ± SD. Mann-Whitney test.\
(E) A dextran uptake assay was performed using human acinar explants. The graph shows quantification of the dextran uptake per single acinar explant. Red lines: mean ± SD. Mann-Whitney test.\
(F) HRP uptake endocytic assay in *Kras*^*G12D*^ acinar explants at the indicated time points. Mean ± SD. Two-tailed *t*-test.\
(G) Acinar explants were starved overnight and then a dextran uptake assay was performed. Each dot represents the uptake in one single acinar explant; red lines: mean ± SD; Mann-Whitney test.\
(H) Lysine-fixable dextran was injected i.v. in 4 weeks-old mice of the indicated genotypes. After 15 min, mice were sacrificed and perfused. Representative total *Z*-stack projections of immunofluorescence staining for dextran and amylase are shown. Dashed lines highlight the acini in the tissue.\
(I) Quantification of (H). Endocytic efficiency was quantified per amylase-positive acini. Red lines: mean ± SD; Mann-Whitney test.\
All scale bars = 50 μm.](gr1){#f0005}

![FPE increases while ADM occurs and is *Rac1* dependent but *Egfr*-dependent.\
(A) Acinar explants were starved overnight, then compounds were added for 10 min and a HRP assay was performed. Mean ± SD. Two tailed *t*-test.\
(B, C) *Kras*^*G12D*^ acinar explants were isolated from at least three mice and seeded in collagen. Monensin or wortmannin were added to the medium and ADM was quantified at day 3. In the scatter dot plots each dot represents the number of structures/optical field. Red lines: mean ± SD. Mann-Whitney test.\
(D) Western blot of *Kras*^*G12D*^ acinar explants treated with the indicated compounds for 10 min.\
(E, F) Acinar explants were starved overnight and treated the next day with refametinib and EGF (25 ng/ml) for the indicated time points. (E) Western blot and (F) HRP uptake assay (*N* = 4 mice). Mean ± SD. Mann-Whitney test.\
(G) Acinar explants were starved overnight. The next day CytD was added together with EGF and a HRP uptake assay was performed. Mean ± SD, two-tailed *t*-test.\
(H) Acinar explants were isolated from mice of the indicated genotypes (2 mice per group) and were then starved overnight. The next day the explants were treated with EGF (25 ng/ml) for 10 min. An HRP uptake assay was performed and normalized to the HRP uptake of untreated acini. Mean ± SD, two-tailed *t*-test.\
(I) Acinar explants were isolated from mice of the indicated genotypes and were then starved overnight. Wild type explants treated with EGF were used as a control. The next day an HRP-assay was performed in triplicates. The increase in FPE of *Kras*^*G12D*^ and *Kras*^*G12D*^*;Rac1*^*Δ/Δ*^ explants compared to the control is shown. Mean ± SD, two-tailed *t*-test.\
(J) Acinar explants were isolated from mice of the indicated genotypes and a dextran endocytic assay was performed. Representative total Z-projections. Scale bars = 50 μm.\
(K) Quantification of the endocytic assay as in (L). Red lines: mean ± SD, Mann-Whitney test.](gr2){#f0010}

![Changes in plasma membrane tension increase FPE and induce ADM independently of *Egfr*.\
(A) Acinar explants from three mice were starved overnight and incubated for 5 min in 0.1% FCS media of different osmolarity. Afterwards a FPE assay was performed. Mean ± SD, two-tailed *t*-test.\
(B) Explants from three mice treated like in (A) were plated in collagen matrix. ADM was quantified at day 3. Mann-Whitney test.\
(C) Acinar explants were treated like in (A). Total protein lysates were extracted immediately after the hypoosmolar treatment and analyzed by Western blot.\
(D) Acinar explants were isolated from mice (up to 14 mice per genotype) and ADM was quantified at day 3. Each dot represents the number of structures/optical field. Red lines: mean ± SD. Mann-Whitney test.\
(E) Dextran uptake assay of *Kras*^*G12D*^*;Egfr*^*Δ/Δ*^ acinar explants treated with hypoosmolar media for 5 min. Red lines: mean; Mann-Whitney test.\
(F) Explants from 4 mice were treated like in (E) and were then plated in collagen matrix. ADM was quantified at day 3. Each dot represents the number of structures/optical field. Red lines: mean ± SD. Mann-Whitney test.\
(G) Immunofluorescence staining showing the rescued phenotype of *Kras*^*G12D*^*;Egfr*^*Δ/Δ*^ explants after hypoosmotic treatment. Scale bars = 50 μm.\
(H) Western blot of *Kras*^*G12D*^*;Egfr*^*Δ/Δ*^ and *Kras*^*G12D*^ acinar explants incubated 5 min with hypoosmotic medium and analyzed at the indicated time points.\
(I) Immunofluorescence staining for ERK1 and the markers for early endosomes (EEA1 and RAB5) in *Kras*^*G12D*^ pancreatic tissue. Dashed lines: ADM lesions. Images were taken by sequential scan of each wavelength to avoid bleed-through. Scale bars = 10 μm.\
(J,K) Western blots of the RAB5 + eluted magnetic fraction (MF) immunoisolated from whole pancreatic tissue (M = marker; P.C. = positive control, whole protein lysate from murine pancreatic cell line).](gr3){#f0015}

![MEK inhibition of hypoosmolar-induced ADM.\
In all panels *Kras*^*G12D*^ acinar explants were isolated and starved overnight. The next day explants were incubated with hypoosmotic (150 mOsm) medium for 5 min and then refametinib was added at the indicated concentrations.\
(A) HRP assay from two mice was performed immediately after the 5 min hypoosmotic treatment. Mean ± SD, two-tailed *t*-test.\
(B) Acinar explants were seeded in collagen and ADM was quantified at day 4. N = number of mice. Mean ± SD, two-tailed *t*-test.\
(C) Representative bright field images of acinar explants described in B. Dashed lines highlight acinar cell clusters, arrowheads: duct-like structures. Scale bars = 50 μm.](gr4){#f0020}

![Oncogenic KRas-driven preneoplastic development requires N-WASP.\
(A) Data were retrieved from PDAC samples from the cBioPortal (TGCA provisional, *N* = 145) and correlation between mRNA expression of the indicated gene pairs was analyzed using the "Plot" tool.\
(B) Immunohistological staining for N-WASP in pancreatic tissue of 4-weeks-old mice of the indicated genotypes.\
(C) Immunohistological staining for N-WASP in pancreatic tissue from mice of the indicated genotypes. Spleens of the same mice were used as internal positive control.\
(D) Western blot of pancreatic tissue of three-month-old mice as indicated.\
(E, F) Immunohistological staining of pancreatic tissue for the ductal marker cytokeratin 19 (CK19) and the PanIN marker mucin 5 AC (MUC5AC) in three-month-old mice.\
(G) Morphometric quantification of preneolastic lesions in mice of the indicated genotypes. *Kras*^*G12D*^ (*N* = 4, 323 optical fields) and *Kras*^*G12D*^*;N-Wasp*^*Δ/Δ*^ (*N* = 3, 186 optical fields). Mean ± SD, Mann-Whitney test.\
(H) Immunohistological staining for P-ERK in pancreatic tissue from three-month-old mice of the indicated genotypes. The insert highlights pancreatic acini.\
(I) Acinar explants from mice with the indicated genotypes (*Kras*^*G12D*^*N* = 5 and *Kras*^*G12D*^*;N-Wasp*^*Δ/Δ*^*N* = 3) were cultured in collagen matrix. ADM was quantified at day 3. Mean and SD are shown, 2-tailed *t*-test.\
(J) Bright field images of explants described in (I). Dashed lines highlight acinar cell clusters. Asterisks mark the ducts.\
(K) Acinar tissue was isolated from littermate mice and acinar explants were starved overnight, then a FPE assay was performed. Mean ± SD.\
All scale bars = 50 μm.](gr5){#f0025}
